Clinical importance and antibiotic resistance of Acinetobacter spp.

Journal of Medical Microbiology

Volumn 46, Issue 9, 1997, Pages 721-746

  Towner, K J ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; TIMENTIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; URINARY TRACT INFECTION;

EID: 0030930124     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-46-9-721     Document Type: Review

References (133)

1. Towner, KJ. Biology of Acinetobacter spp. In: Bergogne-Bérézin E, Joly-Guillou ML, Towner KJ (eds) Acinetobacter: microbiology, epidemiology, infections, management. Boca Raton, CRC Press. 1996: 13-36.
2. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9: 148-165.
3. Piéchaud D, Piéchaud M, Second L. Variétés protéolytiques de Moraxella Iwoffi et de Moraxella glucidolytica (Bact. anitratum). Ann Inst Pasteur 1956; 90: 517-522.
4. Brisou J, Prévot AR. Etudes de systématique bactérienne: révision des espèces réunies dans le genre Achromobacter. Ann Inst Pasteur 1954; 86: 722-728.
5. Bövre K, Henriksen SD. Minimal Standards for description of new taxa within the genera Moraxella and Acinetobacter: Proposal by the Subcommittee on Moraxella and Allied Bacteria. Int J Syst Bacterial 1976; 26: 92-96.
6. Juni E, Genus III. Acinetobacter Brisou and Prévot 1954, 727 AL. In: Krieg NR, Hold JG (eds) Bergey's Manual of systematic bacteriology, vol 1. Baltimore, Williams and Wilkins. 1984: 303-307.
7. Clew RH, Moellering RC, Kunz LJ. Infections with Acinetobacter calcoaceticus (Herellea vaginicola). Clinical and laboratory studies. Medicine 1977; 56: 79-97.
8. Ramphal R, Kluge RM. Acinetobacter calcoaceticus variety anitratus: an increasing nosocomial problem. Am J Med Sci 1979; 277: 57-66.
9. French GL, Casewell MW, Roncoroni AJ, Knight S, Phillips I. A hospital outbreak of antibiotic-resistant Acinetobacter anitratus: epidemiology and control. J Hosp Infect 1980; 1: 125-131.
10. Vila J, Almela M, Jimenez de Anta MT. Laboratory investigation of hospital outbreak caused by two different multiresistant Acinetobacter calcoaceticus subsp. anitratus strains. J Clin Microbiol 1989; 27: 1086-1089.
11. Struelens MJ, Carlier E, Maes N, Serruys E, Quint WGV, van Belkum A. Nosocomial colonization and infection with multiresistant Acinetobacter baumannii: outbreak delineation using DNA macrorestriction analysis and PCR-fingerprinting. J Hosp Infect 1993; 25: 15-32.
12. Green AR, Milling MAP. Infection with Acinetobacter in burns unit. Burns 1983; 9: 292-294.
13. Bergogne-Bérézin E, Joly-Guillou ML. An underestimated nosocomial pathogen. Acinetobacter calcoaceticus. J Antimicrob Chemother 1985; 16: 535-538.
14. Hartstein AI, Rashad AL, Liebler JM et al. Multiple intensive care unit outbreak of Acinetobacter calcoaceticus subspecies anitratus respiratory infection and colonization associated with contaminated, reusable ventilator circuits and resuscitation bags. Am J Med 1988; 85: 624-631.
15. Bergogne-Bérézin E, Joly-Guillou ML, Vieu JF. Epidemiology of nosocomial infections due to Acinetobacter calcoaceticus. J Hosp Infect 1987; 10: 105-113.
16. Joly-Guillou ML, Bergogne-Bérézin E, Vieu JF. Epidémiologie et résistance aux antibiotiques d'Acinetobacter en milieu hospitalier: bilan de 5 années. Presse Med 1990; 19: 357-361.
17. Bergogne-Bérézin E. Resistance of Acinetobacter spp. to antimicrobials - overview of clinical resistance patterns and therapeutic problems. In: Bergogne-Bérézin E, Joly-Guillou ML, Towner KJ (eds) Acinetobacter: microbiology, epidemiology, infections, management, Boca Raton, CRC Press. 1996: 133-183.
18. Levi I, Rubinstein E. Acinetobacter infections - overview of clinical features. In: Bergogne-Bérézin E, Joly-Guillou ML, Towner KJ (eds) Acinetobacter: microbiology, epidemiology, infections, management. Boca Raton, CRC Press. 1996 101-115.
19. Joly-Guillou ML, Deeré D, Wolff M, Bergogne-Bérézin E. Acinetobacter spp.: clinical epidemiology in 89 intensive care units. A retrospective study in France during 1991. 2nd International Conference on the Prevention of Infection (CIPI), Nice, 1992; abstract CJI.
20. Seifert H, Baginski R, Schulze A, Pulverer G. Antimicrobial susceptibility of Acinetobacter species. Antimicrob Agents Chemother 1993; 37: 750-753.
21. Buxton AE, Anderson RL, Werdegar D, Atlas E. Nosocomial respiratory tract infection and colonization with Acinetobacter calcoaceticus. Epidemiologic characteristics. Am J Med 1978; 65: 507-513.
22. Cefai C, Richards J, Gould FK, McPeake P. An outbreak of Acinetobacter respiratory tract infection, resulting from incomplete disinfection of ventilatory equipment. J Hosp Infect 1990; 15: 117-182.
23. Chastre J, Trouillet JL, Vuagnat A, Joly-Guillou ML. Nosocomial pneumonia caused by Acinetobacter spp. In: Bergogne-Bérézin E, Joly-Guillou ML, Towner KJ (eds) Acinetobacter: microbiology, epidemiology, infections, management. Boca Raton, CRC Press. 1996: 117-132.
24. Siegman-Ingra Y, Bar Yosef S, Gorea A, Avram J. Nosocomial Acinetobacter meningitis secondary to invasive procedures: report of 25 cases and review. Clin Infect Dis 1993; 17: 843-849.
25. Joly-Guillou ML, Brun-Buisson C. Epidemiology of Acinetobacter spp.: surveillance and management of outbreaks. In: Bergogne-Bérézin E, Joly-Guillou ML, Towner KJ (eds) Acinetobacter microbiology, epidemiology, infections, management. Boca Raton, CRC Press. 1996: 71-100.
26. Beijerinck MW. Über Pigmentbildung bei Essigbakterien. Centralbl Bakteriol Parasit 1911; 29: 169-176.
27. Baumann P, Doudoroff M, Stanier RY. A study of the Moraxella group. II. Oxidative-negative species (genus Acinetobacter). J Bacterial 1968; 95: 1520-1541.
28. Lautrop H. Acinetobacter. In: Buchanan RE, Gibbons NE (eds) Bergey's Manual of determinative bacteriology, 8th edn. Baltimore, Williams and Wilkins, 1974: 436-438.
29. Bouvet PJM, Grimont PAD. Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov., Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp. nov., and Acinetobacter junii sp, nov. and emended descriptions of Acinetobacter calcoaceticus and Acinetobacter Iwoffii. Int J Syst Bacteriol 1986; 36: 228-240.
30. Bouvet PJM, Jeanjean S. Delineation of new proteolytic genomic species in the genus Acinetobacter. Res Microbiol 1989; 140: 291-299.
31. Tjernberg I, Ursing J. Clinical strains of Acinetobacter classified by DNA-DNA hybridization. APMIS 1989; 97: 595-605.
32. Nishimura Y, Ino T, Iizuka H. Acinetobacter radioresistens sp. nov. isolated from cotton and soil. Int J Syst Bacteriol 1988; 38: 209-211.
33. Nishimura Y, Kano M, Ino T, Iizuka H, Kosako Y, Kaneko T. Deoxyribonucleic acid relationship among the radiation-resistant Acinetobacter and other Acinetobacter. J Gen Appl Microbiol 1987; 33: 371-376.
34. Gerner-Smidt P, Tjernberg I, Ursing J. Reliability of phenotypic tests for identification of Acinetobacter species. J Clin Microbiol 1991; 29: 277-282.
35. Kämpfer P, Tjernberg I, Ursing J. Numerical classification and identification of Acinetobacter genomic species. J Appl Bacteriol 1993; 75: 259-268.
36. Bernards AT, Dijkshoorn L, van der Toorn J, Bochner BR, van Boven CPA. Phenotypic characterisation of Acinetobacter strains of 13 DNA-DNA hybridisation groups by means of the Biolog system. J Med Microbiol 1995; 42: 113-119.
37. Bernards AT, van der Toorn J, van Boven CPA, Dijkshoorn L. Evaluation of the ability of a commercial system to identify Acinetobacter genomic species. Eur J Clin Microbiol Infect Dis 1996; 15: 303-308.
38. Bouvet PJM, Jeanjean S. Differentiation of Acinetobacter calcoaceticus sensu stricto from related Acinetobacter species by elcctrophoretic polymorphism of malate dehydrogenase, glutamate dehydrogenase and catalase. Res Microbiol 1995; 146: 773-785.
39. Dijkshoorn L. Acinetobacter - microbiology. In: Bergogne-Bérézin E, Joly-Guillou ML, Towner KJ (eds) Acinetobacter: microbiology, epidemiology, infections, management. Boca Raton, CRC Press. 1996: 37-69.
40. Gerner-Smidt P. Ribotyping of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Clin Microbiol 1992; 30: 2680-2685.
41. Janssen P, Coopman R, Huys G et al. Evaluation of the DNA fingerprinting method AFLP as a new tool in bacterial taxonomy. Microbiology 1996; 142: 1881-1893.
42. Vaneechoutte M, Dijkshoorn L, Tjernberg I et al. Identification of Acinetobacter genomic species by amplified ribosomal DNA restriction analysis. J Clin Microbiol 1995; 33: 11-15.
43. Ehrenstein B, Bernards AT, Dijkshoorn L et al. Acinetobacter species identification by using tRNA spacer fingerprinting. J Clin Microbiol 1996; 34: 2414-2420.
44. Nowak A, Burkiewicz A, Kur J, PCR differentiation of seventeen genospecies of Acinetobacter. FEMS Microbiol Lett 1995; 126: 181-187.
45. Nowak A, Kur J. Genomic species typing of acinetobacters by polymerase chain reaction amplification of the recA gene. FEMS Microbiol Lett 1995; 130: 327-332.
46. Yamamoto S, Harayama S. Phylogenetic analysis of Acinetobacter strains based on the nucleotide sequences of gyrB genes and on the amino acid sequences of their products. Int J Syst Bacteriol 1996; 46: 506-511.
47. Bouvet PJM, Grimont PAD. Identification and biotyping of clinical isolates of Acinetobacter. Ann Inst Pasteur/Microbiol 1987; 138: 569-578.
48. Crowe M, Towner KJ, Humphreys H. Clinical and epidemiological features of an outbreak of acinetobacter infection in an intensive therapy unit. J Med Microbiol 1995; 43: 55-62.
49. Webster CA, Towner KJ, Humphreys H, Ehrenstein B, Hartung D, Grundmann H. Comparison of rapid automated laser fluorescence analysis of DNA fingerprints with four other computer-assisted approaches for studying relationships between Acinetobacter baumannii isolates. J Med Microbiol 1996; 44: 185-194.
50. Seifert H, Schulze A, Baginski R, Pulverer G. Comparison of four different methods for epidemiologic typing of Acinetobacter baumannii. J Clin Microbiol 1994; 32: 1816-1819.
51. Janssen P, Dijkshoorn L. High resolution DNA fingerprinting of Acinetobacter outbreak strains. FEMS Microbiol Lett 1996; 142: 191-194.
52. Dijkshoorn L, Aucken H, Gerner-Smidt P et al. Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods. J Clin Microbiol 1996; 34: 1519-1525.
53. Bergogne-Bérézin E, Joly-Guillou ML. Antibiotic resistance mechanisms in Acinetobacter. In: Towner KJ, Bergogne-Bérézin E, Fewson CA (eds) The biology of Acinetobacter: taxonomy, clinical importance, molecular biology, physiology, industrial relevance. New York, Plenum. 1991: 83-115.
54. Fass RJ, Bamishan J, Ayers LW. Emergence of bacterial resistance to imipenem and ciprorloxacin in a university hospital. J Antimicrob Chemother 1995; 36: 343-353.
55. Kljucar S, Heimesaat M, v. Pritzbuer E et al. Rationale for different dosing regimens of ciprorloxacin i.v. in the treatment of nosocomial infections. 6th International Congress for Infectious Diseases, Prague, 1994; abstract 907.
56. Bauernfeind A, Schweighart S, Eberlein E, Rotter G. Bactericidal kinetics of ampicillin plus sulbactam for Acinetobacter baumannii and Acinetobacter Iwoffii. 5th European Congress of Clinical Microbiology and Infectious Diseases, Oslo, 1991; abstract 1760.
57. Bauernfeind A. Questioning dosing regimens of ciprofloxacin. J Antimicrob Chemother 1993; 31: 789-798.
58. Joly-Guillou ML, Deere D, Bergogne-Bérézin E. Infections nosocomiales a Acinetobacter: surveillance epidemiologique hospitaliere. Bull Epidemiol Hebdominare 1992; vL: 211-212.
59. Amyes SGB, Young H-K. Mechanisms of antibiotic resistance in Acinetobacter spp. - genetics of resistance. In: Bergogne-Bérézin E, Joly-Guillou ML, Towner KJ (eds) Acinetobacter. microbiology, epidemiology, infections. management. Boca Raton, CRC Press. 1996: 185-223.
60. Goldstein FW, Labigne-Roussel A, Gerbaud G, Carlier C, Collatz E, Courvalin P. Transferable plasmid-mediated antibiotic resistance in Acinetobacter. Plasmid 1983; 10: 138-147.
61. Joly-Guillou ML, Vallée U, Bergogne-Bérézin E, Philippon A. Distribution of beta-lactamases and phenotype analysis in clinical strains of Acinetobacter calcoaceticus. J Antimicrob Chemother 1988; 22: 597-604.
62. Matthew M, Harris AM. Identification of β-lactamases by analytical isoelectric focusing: correlation with bacterial taxonomy. J Gen Microbiol 1976; 94: 55-67.
63. Medeiros AA, Hare R, Papa E, Adam C, Miller GH. Gram-negative bacilli resistant to third-generation cephalosporins: β-lactamase characterization and susceptibility to Sch 34343. J Antimicrob Chemother 1985; 15 Suppl C: 119-132.
64. Joly-Guillou ML, Bergogne-Bérézin E, Moreau N. Enzymatic resistance to β-lactams and aminoglycosides in Acinetobacter calcoaceticus. J Antimicrob Chemother 1987; 20: 773-776.
65. Hikida M, Yoshisa M, Mitsuhashi S, Inoue M. Purification and properties of a cephalosporinase from Acinetobacter calcoaceticus. J Antibiot 1989; 42: 123-126.
66. Morohoshi T, Saito T. β-lactamase and β-lactam resistance in Acinetobacter anitratum. J Antibiot 1977; 30: 969-973.
67. Hood J, Amyes SGB. A novel method for the identification and distinction of the beta-lactamases of the genus Acinetobacter. J Appl Bacteriol 1989; 67: 157-163.
68. Perilli M, Felici A, Oratore A ft al. Characterization of the chromosomal cephalosporinases produced by Acinetobacter Iwoffi and Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother 1996; 40: 715-719.
69. Hood J, Amyes SGB. The chromosomal beta-lactamases of the genus Acinetobacter: enzymes which challenge our imagination. In: Towner KJ, Bergogne-Bérézin E, Fewson CA (eds) The biology of Acinetobacter: taxonomy, clinical importance, molecular biology, physiology, industrial relevance. New York, Plenum. 1991: 117-132.
70. Tankovic J, Legrand P, De Gatines G, Chemineau V, Brun-Buisson G, Duval J. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. J Clin Microbiol 1994; 32: 2677-2681.
71. Paton RH, Miles RS, Hood J, Amyes SOB. ARI I: beta-lactamase-mediated imipenem resistance in Acinetobacter baumannii. Int J Antimicrob Agents 1993; 2: 81-88.
72. Brown S, Bantar C, Young H-K et al. An outbreak of imipenem resistance in Acinetobacter strains from Buenos Aires, Argentina. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy 1996; C122.
73. Scaife W, Young H-K, Paton RH, Amyes SGB. Transferable imipenem-resistance in Acinetobacter species from a clinical source. J Antimicrob Chemother 1995; 36: 585-586.
74. Pérez AN, Bonet IC, Robledo EH, Abascal R, Pious CV Metallo-β-lactamases in Acinetobacter calcoaceticus? Med Sci Res 1996; 24: 315-317.
75. Fass RJ, Gregory WW, D'Amato RF, Matsen JM, Wright DM, Young LS. In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and non-fermenters. Antimicrob Agents Chemother 1990; 34: 2256-2259.
76. Obana Y, Nishino T. In-vitro and in-vivo activities of sulbactam and YTR830H against Acinetobacter calcoaceticus. J Antimicrob Chemother 1990; 26: 677-682.
77. Aubert G, Guichard D, Vedel G. In-vitro activity of cephalosporins alone and combined with sulbactam against various strains of Acinetobacter baumannii with different antibiotic resistance profiles. J Antimicrob Chemother 1996; 37: 155-160.
78. Soussy CF. Sensibilité aux aminosides: bilan annuel d'un CHU Lett Infectiol 1995; juin; 6-10.
79. Miller GH and the aminoglycosidc study groups. Increasing complexity of aminoglycoside resistance mechanisms in gram-negative bacteria. APUA Newsletter 1994; 12: 5-8.
80. Lambert T, Gerbaud G, Courvalin P. Transferable amikacin resistance in Acinetobacter spp. due to a new type of 3′-aminoglycoside phosphotransferase. Antimicrob Agents Chemother 1988; 32: 15-19.
81. Lambert T, Gerbaud G, Courvalin P. Characterization of transposon Tn/528, which confers amikacin resistance by synthesis of aminoglycoside 3′-O-phosphotransferase type VI. Antimicrob Agents Chemother 1994; 38: 702-706.
82. Recchia GD, Hall RM. Gene cassettes: a new class of mobile element. Microbiology 1995; 141: 3015-3027.
83. Lambert T, Gerbaud G, Courvalin P. Characterization of the chromosomal aac(6′)-Ij gene of Acinetobacter sp. 13 and the aac(6′)-Ih plasmid gene of Acinetobacter baumannii. Antimicrob Agents Chemother 1994; 38: 1883-1889.
84. Lambert T, Gerbaud G, Galimand M, Courvalin P. Characterization of Acinetobacter haemolyticus aac(6′)-Ig gene encoding an aminoglycoside 6′-N-acetyltransferase which modifies amikacin. Antimicrob Agents Chemother 1993; 37: 2093-2100.
85. Rudant E, Bourlioux P, Courvalin P, Lambert T. Characterization of the aac(6′)-Ik gene of Acinetobacter sp. 6. FEMS Microbiol Lett 1994; 124: 49-54.
86. Berg KL, Squires CL, Squires C. In vivo translation of a region within the rrnB 16 rRNA gene of Escherichia coli. J Bacteriol 1987; 169: 1691-1701.
87. Ploy M-C, Giamarellou H, Bourlioux P, Courvalin P, Lambert T. Detection of aac(6′)-I genes in amikacin-resistant Acinetobacter spp. by PCR. Antimicrob Agents Chemother 1994; 38: 2925-2928.
88. Wagner LA, Weiss RB, Driscoll R, Dunn DS, Gesteland RF. Transcriptional slippage occurs during elongation at runs of adenine or thymine in Escherichia coli. Nucleic Acids Res 1990; 18: 3529-3535.
89. Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycosidc-modifying enzymes. Microbiol Rev 1993; 57: 138-163.
90. Shaw KJ, Rather PN, Sabatelli FJ et al. Characterization of the chromosomal aac(6′)-Ic gene from Serratia marcescens. Antimicrob Agents Chemother 1992; 36: 1447-1455.
91. Rather PN, Orosz E, Shaw KJ, Hare R, Miller G. Characterization and transcriptional regulation of the 2′-N-acetyltransferase gene from Providencia stuartii. J Bacteriol 1993; 175: 6492-6498.
92. Snelling AM, Hawkey PM, Heritage J, Downey P, Bennett PM, Holmes B. The use of a DNA probe and PCR to examine the distribution of the aac(6′)-Ic gene in Serratia marcescens and other gram-negative bacteria. J Antimicrob Chemother 1993; 31: 841-854.
93. Tilley PAG, Roberts FJ. Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical settings. Clin Infect Dis 1994; 18: 896-900.
94. Beck-Sagué CM, Jarvis WR, Brook JH et al. Epidemic bacteremia due to Acinetobacter baumannii in five intensive care units. Am J Epidemiol 1990; 132: 723-733.
95. Holton J. A report of a further hospital outbreak caused by a multi-resistant Acinetobacter anitratus. J Hosp Infect 1982; 3: 305-309.
96. Marcos MA, Abdalla S, Pedraza F et al. Epidemiological markers of Acinetobacter baumannii clinical isolates from a spinal cord injury unit. J Hosp Infect 1994; 28: 39-48.
97. Godineau-Gauthey N, Lesage D, Tessier F, Kollia D, Daguet GL. Acinetobacter calcoaceticus variete anitratus ou Acinetobacter baumannii. Etude de la sensibilite aux antibiotiques de 65 souches hospitalaries. Med Mal Infect 1988; 2: 124-127.
98. King A, Phillips I. The comparative in-vitro activity of eight newer quinolones and nalidixic acid. J Antimicrob Chemother 1986; 18 Suppl D: 1-20.
99. Rolston KVI, Ho DH, LeBlanc B, Gooch G, Bodely GP. Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients. Eur J Clin Microbiol Infect Dis 1988; 7: 684-686.
100. Acar JF, O'Brien TF, Goldstein FW, Jones RN. The epidemiology of bacterial resistance to quinolones. Drugs 1993; 45 Suppl 3: 24-28.
101. Traub WH, Spohr M. Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3, and genospecies 6). Antimicrob Agents Chemother 1989; 33: 1617-1619.
102. Vila J, Marcos A, Marco F et al. In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1993; 37: 138-141.
103. Hooper DC, Wolfson JS. Mechanisms of bacterial resistance to quinolones. In: Quinolone antibacterial agents, 2nd edn. Washington DC, American Society for Microbiology. 1993: 97-118.
104. Cohen SP, Hooper DC, Wolfson JS, Souza KS, McMurry LM, Levy SB. Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob Agents Chemother 1988; 32: 1187-1191.
105. Cohen SP, McMurry LM, Hooper DC, Wolfson JS, Levy SB. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob Agents Chemother 1989; 33: 1318-1325.
106. Hirai K, Aoyama H, Irikura T, Iyobe S, Mitsuhashi S. Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother 1986; 29: 535-538.
107. Hirai K, Aoyama H, Suzue S, Irikura T, Iyobe S, Mitsuhashi S. Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother 1986; 30: 248-253.
108. Hooper DC, Wolfson JS, Bozza MA, Ng EY. Genetics and regulation of outer membrane protein expression by quinolone resistance loci nfxB, nfxC, and cfxB. Antimicrob Agents Chemother 1992; 36: 1151-1154.
109. Hooper DC, Wolfson JS, Souza KS, Ng EY, McHugh GL, Swartz MN. Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation. Antimi- crob Agents Chemother 1989; 33: 283-290.
110. Vila J, Ruiz J, Marco F et al. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother 1994; 38: 2477-2479.
111. Yamagishi J, Yoshida H, Yamayoshi H, Nakamura S. Naxildixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet 1986; 204: 367-373.
112. Yoshida H, Bogaki M, Nakamura M, Yamanaka LM, Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother 1991; 35: 1647-1650.
113. Nakamura S, Nakamura M, Kojima T, Yoshida H. gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli. Antimicrob Agents Chemother 1989; 33: 254-255.
114. Ouabdesselam S, Hooper DC, Tankovic J, Soussy CJ. Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. Antimicrob Agents Chemother 1995; 39: 1667-1670.
115. Khodursky AB, Ziechiedrich EL, Cozzarelli NR. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci USA 1995; 92: 11801-11805.
116. Vila J, Ruiz J, Goni P, Jimenez de Anta MT. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother 1996; 40: 491-493.
117. Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 1996; 40: 879-885.
118. Marcos MA, Jimenez de Anta MT, Vila J. Correlation of six methods for typing nosocomial isolates of Acinetobacter baumannii. J Med Microbiol 1995; 42: 328-335.
119. Ferrero L., Cameron B, Manse B et al. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinones. Mol Microbiol 1994; 13: 641-653.
120. Ruiz J, Casellas S, Jimenez de Anta MT, Vila J. The region of the parE gene, homologous to the quinolone-resistant determining region of the gyrB gene, is not linked with the acquisition of quinolone resistance in Escherichia coli clinical isolates. J Antimicrob Chemother 1997 (in press).
121. Sato K, Nakae T. Outer membrane permeability of Acinetobacter calcoaceticus and its implications in antibiotic resistance. J Antimicrob Chemother 1991; 28: 35-45.
122. Angus BL, Carey AM, Caron DA, Kropinski AMB, Hancock REW. Outer membrane permeability in Pseudomonas aerugi- nosa: comparison of a wild-type with an antibiotic-super-susceptible mutant. Antimicrob Agents Chemother 1982; 21: 299-309.
123. Yoshimura F, Nikaido H. Permeability of Pseudomonas aeruginosa outer membrane to hydrophilic solutes. J Bacteriol 1982; 152: 636-642.
124. Li XZ, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother 1994; 38: 1732-1741.
125. Joly-Guillou ML, Bergogne-Bérézin E, Vieu JF. Epidemiology of Acinetobacter strains isolated from nosocomial infections in France. In: Towner KJ, Bergogne-Bérézin E, Fewson CA (eds) The biology of Acinetobacter: taxonomy, clinical importance, molecular biology, physiology, industrial relevance. New York, Plenum. 1991: 63-68.
126. Obana Y. Pathogenic significance of Acinetobacter calcoaceticus: analysis of experimental infection in mice. Microbiol Immunol 1986; 30: 645-657.
127. Wolff M, Joly-Guillou ML. In-vivo efficacy of β-lactamase inhibitors alone and in combination against Acinetobacter baumannii in a mouse pneumonia model. Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, American Society for Microbiology, 1996: abstract B61.
128. Davis BD, Dulbecco R, Eisen HN, Ginsberg US, Wood WB. Microbiology; including immunology and molecular genetics, 2nd edn. Hagerstown, Harper and Row. 1973: 751.
129. Mayhall CG. Infections in burn patients. In: Wenzel RP (ed) CRC handbook of hospital infections. Boca Raton, CRC Press. 1981: 317-339.
130. Chastre J, Trouillet J-L, Vuagnat A, Joly-Guillou M-L. Nosocomial pneumonia caused by Acinetobacter spp. In: Bergogne-Bérézin E, Joly-Guillou ML, Towner KJ (eds) Acinetobacter: microbiology, epidemiology, infections, management. Boca Raton, CRC Press. 1996: 117-132.
131. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94: 281-288.
132. Fagon JY, Chastre J, Domart Y et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989; 139: 877-884.
133. Levi I, Rubinstein E. Acinetobacter infections - overview of clinical features. In: Bergogne-Bérézin E, Joly-Guillou ML, Towner KJ (eds) Acinetobacter: microbiology, epidemiology, infections, management. Boca Raton. CRC Press. 1996: 101-115.